{"count": 8, "results": [{"_id": "33938788", "pmid": 33938788, "title": "Fixed-dose combination amlodipine-celecoxib for treatment of hypertension and osteoarthritis pain: an up-to-date evaluation.", "journal": "Expert Opin Pharmacother", "authors": ["Piszczatoski CR", "Smith SM"], "date": "2021-08-01T00:00:00Z", "doi": "10.1080/14656566.2021.1915289", "meta_date_publication": "2021 Aug", "meta_volume": "22", "meta_issue": "11", "meta_pages": "1381-1385", "score": 50257.2, "text_hl": "Introduction: A fixed-dose combination of @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ and @CHEMICAL_Celecoxib @CHEMICAL_MESH:D000068579 @@@celecoxib@@@, branded in the USA as Consensi , was recently granted a US Food and Drug Administration (FDA)-approved indication for treatment of comorbid @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@ and @<m>DISEASE_Osteoarthritis</m> @DISEASE_MESH:D010003 @@@osteoarthritis@@@.Areas covered: A PubMed and Medline search was conducted for clinical trials published through December 2020 in the English language using keywords @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@, @CHEMICAL_Celecoxib @CHEMICAL_MESH:D000068579 @@@celecoxib@@@, combination product, consensi, @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@, @<m>DISEASE_Osteoarthritis</m> @DISEASE_MESH:D010003 @@@osteoarthritis@@@, and pill burden. ", "citations": {"NLM": "Piszczatoski CR, Smith SM. Fixed-dose combination amlodipine-celecoxib for treatment of hypertension and osteoarthritis pain: an up-to-date evaluation. Expert Opin Pharmacother. 2021 Aug;22(11):1381-1385. PMID: 33938788", "BibTeX": "@article{33938788, title={Fixed-dose combination amlodipine-celecoxib for treatment of hypertension and osteoarthritis pain: an up-to-date evaluation.}, author={Piszczatoski CR and Smith SM}, journal={Expert Opin Pharmacother}, volume={22}, number={11}, pages={1381-1385}}"}}, {"_id": "32526403", "pmid": 32526403, "title": "An enhanced first derivative synchronous spectrofluorimetric method for determination of the newly co-formulated drugs, amlodipine and celecoxib in pharmaceutical preparation and human plasma.", "journal": "Spectrochim Acta A Mol Biomol Spectrosc", "authors": ["Attala K", "Eissa MS", "Hasan MA", "El-Henawee MM", "Abd El-Hay SS"], "date": "2020-10-15T00:00:00Z", "doi": "10.1016/j.saa.2020.118533", "meta_date_publication": "2020 Oct 15", "meta_volume": "240", "meta_issue": "", "meta_pages": "118533", "score": 50254.16, "text_hl": "BACKGROUND: A new combination of @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ and @CHEMICAL_Celecoxib @CHEMICAL_MESH:D000068579 @@@celecoxib@@@ has been recently introduced in order to relieve the symptoms of @<m>DISEASE_Osteoarthritis</m> @DISEASE_MESH:D010003 @@@osteoarthritis@@@ and help treat @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@ that commonly associated with @<m>DISEASE_Osteoarthritis</m> @DISEASE_MESH:D010003 @@@osteoarthritis@@@. ", "citations": {"NLM": "Attala K, Eissa MS, Hasan MA, El-Henawee MM, Abd El-Hay SS. An enhanced first derivative synchronous spectrofluorimetric method for determination of the newly co-formulated drugs, amlodipine and celecoxib in pharmaceutical preparation and human plasma. Spectrochim Acta A Mol Biomol Spectrosc. 2020 Oct 15;240():118533. PMID: 32526403", "BibTeX": "@article{32526403, title={An enhanced first derivative synchronous spectrofluorimetric method for determination of the newly co-formulated drugs, amlodipine and celecoxib in pharmaceutical preparation and human plasma.}, author={Attala K and Eissa MS and Hasan MA and El-Henawee MM and Abd El-Hay SS}, journal={Spectrochim Acta A Mol Biomol Spectrosc}, volume={240}, pages={118533}}"}}, {"_id": "32882657", "pmid": 32882657, "title": "Smart UV spectrophotometric methods based on simple mathematical filtration for the simultaneous determination of celecoxib and ramipril in their pharmaceutical mixtures with amlodipine: A comparative statistical study.", "journal": "Spectrochim Acta A Mol Biomol Spectrosc", "authors": ["Attala K", "Elsonbaty A"], "date": "2021-01-05T00:00:00Z", "doi": "10.1016/j.saa.2020.118853", "meta_date_publication": "2021 Jan 5", "meta_volume": "244", "meta_issue": "", "meta_pages": "118853", "score": 50248.68, "text_hl": "Two newly introduced pharmaceutical mixtures of @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@/@CHEMICAL_Celecoxib @CHEMICAL_MESH:D000068579 @@@celecoxib@@@ and @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@/@CHEMICAL_Ramipril @CHEMICAL_MESH:D017257 @@@ramipril@@@ were developed to manage @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@ and the associated @<m>DISEASE_Osteoarthritis</m> @DISEASE_MESH:D010003 @@@osteoarthritis@@@. ", "citations": {"NLM": "Attala K, Elsonbaty A. Smart UV spectrophotometric methods based on simple mathematical filtration for the simultaneous determination of celecoxib and ramipril in their pharmaceutical mixtures with amlodipine: A comparative statistical study. Spectrochim Acta A Mol Biomol Spectrosc. 2021 Jan 5;244():118853. PMID: 32882657", "BibTeX": "@article{32882657, title={Smart UV spectrophotometric methods based on simple mathematical filtration for the simultaneous determination of celecoxib and ramipril in their pharmaceutical mixtures with amlodipine: A comparative statistical study.}, author={Attala K and Elsonbaty A}, journal={Spectrochim Acta A Mol Biomol Spectrosc}, volume={244}, pages={118853}}"}}, {"_id": "30240679", "pmid": 30240679, "title": "Fixed-Dose Combination Amlodipine/Celecoxib (Consensi) for Hypertension and Osteoarthritis.", "journal": "Am J Med", "authors": ["Smith SM", "Cooper-DeHoff RM"], "date": "2019-02-01T00:00:00Z", "doi": "10.1016/j.amjmed.2018.08.027", "meta_date_publication": "2019 Feb", "meta_volume": "132", "meta_issue": "2", "meta_pages": "172-174", "score": 50067.95, "text_hl": "Fixed-Dose Combination @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@Amlodipine@@@/@CHEMICAL_Celecoxib @CHEMICAL_MESH:D000068579 @@@Celecoxib@@@ (Consensi) for @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@Hypertension@@@ and @<m>DISEASE_Osteoarthritis</m> @DISEASE_MESH:D010003 @@@Osteoarthritis@@@.", "citations": {"NLM": "Smith SM, Cooper-DeHoff RM. Fixed-Dose Combination Amlodipine/Celecoxib (Consensi) for Hypertension and Osteoarthritis. Am J Med. 2019 Feb;132(2):172-174. PMID: 30240679", "BibTeX": "@article{30240679, title={Fixed-Dose Combination Amlodipine/Celecoxib (Consensi) for Hypertension and Osteoarthritis.}, author={Smith SM and Cooper-DeHoff RM}, journal={Am J Med}, volume={132}, number={2}, pages={172-174}}"}}, {"_id": "30362840", "pmid": 30362840, "title": "Amlodipine and celecoxib for treatment of hypertension and osteoarthritis pain.", "journal": "Expert Rev Clin Pharmacol", "authors": ["Angeli F", "Trapasso M", "Signorotti S", "Verdecchia P", "Reboldi G"], "date": "2018-11-01T00:00:00Z", "doi": "10.1080/17512433.2018.1540299", "meta_date_publication": "2018 Nov", "meta_volume": "11", "meta_issue": "11", "meta_pages": "1073-1084", "score": 50064.41, "text_hl": "Just recently, a single tablet combination of @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine besylate@@@, a calcium channel blocker, and @CHEMICAL_Celecoxib @CHEMICAL_MESH:D000068579 @@@celecoxib@@@, a nonsteroidal anti-inflammatory drug, indicated for @SPECIES_9606 @@@patients@@@ for whom treatment with @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ for @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@ and @CHEMICAL_Celecoxib @CHEMICAL_MESH:D000068579 @@@celecoxib@@@ for @<m>DISEASE_Osteoarthritis</m> @DISEASE_MESH:D010003 @@@osteoarthritis@@@ are appropriate, has been recently approved. ", "citations": {"NLM": "Angeli F, Trapasso M, Signorotti S, Verdecchia P, Reboldi G. Amlodipine and celecoxib for treatment of hypertension and osteoarthritis pain. Expert Rev Clin Pharmacol. 2018 Nov;11(11):1073-1084. PMID: 30362840", "BibTeX": "@article{30362840, title={Amlodipine and celecoxib for treatment of hypertension and osteoarthritis pain.}, author={Angeli F and Trapasso M and Signorotti S and Verdecchia P and Reboldi G}, journal={Expert Rev Clin Pharmacol}, volume={11}, number={11}, pages={1073-1084}}"}}, {"_id": "25573427", "pmid": 25573427, "pmcid": "PMC4296554", "title": "Positive side effects of Ca antagonists for osteoarthritic joints:results of an in vivo pilot study", "journal": "J Orthop Surg Res", "authors": ["Daniilidis K", "Georges P", "Tibesku CO", "Prehm P"], "date": "2015-01-09T00:00:00Z", "doi": "10.1186/s13018-014-0138-8", "meta_date_publication": "2015 Jan 9", "meta_volume": "10", "meta_issue": "", "meta_pages": "1", "score": 50063.324, "text_hl": "@CHEMICAL_Nifedipine @CHEMICAL_MESH:D009543 @@@Adalat@@@, @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@Amlodipine@@@, Carmen, Nitrendipin, and @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@Norvasc@@@ lead to an improvement.", "citations": {"NLM": "Daniilidis K, Georges P, Tibesku CO, Prehm P. Positive side effects of Ca antagonists for osteoarthritic joints:results of an in vivo pilot study J Orthop Surg Res. 2015 Jan 9;10():1. PMID: 25573427", "BibTeX": "@article{25573427, title={Positive side effects of Ca antagonists for osteoarthritic joints:results of an in vivo pilot study}, author={Daniilidis K and Georges P and Tibesku CO and Prehm P}, journal={J Orthop Surg Res}, volume={10}, pages={1}}"}}, {"_id": "21568075", "pmid": 21568075, "title": "[Merits of paracetamol in osteoarthritic hypertensive patients].", "journal": "Acta Med Croatica", "authors": ["Pavlicević I", "Kuzmanić M", "Rumboldt M", "Rumboldt Z"], "date": "2011-03-01T00:00:00Z", "meta_date_publication": "2011 Mar", "meta_volume": "65", "meta_issue": "1", "meta_pages": "55-62", "score": 50052.367, "text_hl": "Following clinical work-up and NSAID discontinuation for at least 3 days (run-in period of only 3-7 days), @<m>DISEASE_Osteoarthritis</m> @DISEASE_MESH:D010003 @@@osteoarthritis@@@ subjects were randomized to 1-month periods of @CHEMICAL_Ibuprofen @CHEMICAL_MESH:D007052 @@@ibuprofen@@@ (400-600 mg t.i.d.) or @CHEMICAL_Piroxicam @CHEMICAL_MESH:D010894 @@@piroxicam@@@ (10-20 mg o.d.) with one month of @CHEMICAL_Acetaminophen @CHEMICAL_MESH:D000082 @@@paracetamol@@@ (1000 mg t.i.d.) in the middle as a \"wash-out\" interval, continuing the prescribed @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ (5-10 mg o.d.) or @CHEMICAL_Lisinopril @CHEMICAL_MESH:D017706 @@@lisinopril@@@/@CHEMICAL_Hydrochlorothiazide @CHEMICAL_MESH:D006852 @@@hydrochlorothiazide@@@ fixed drug combination (10/6.25-20/12.5 mg o.d.), while control subjects (@DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertensives@@@ with no @<m>DISEASE_Osteoarthritis</m> @DISEASE_MESH:D010003 @@@osteoarthritis@@@) were just keeping their antihypertensive therapy. ", "citations": {"NLM": "Pavlicević I, Kuzmanić M, Rumboldt M, Rumboldt Z. [Merits of paracetamol in osteoarthritic hypertensive patients]. Acta Med Croatica. 2011 Mar;65(1):55-62. PMID: 21568075", "BibTeX": "@article{21568075, title={[Merits of paracetamol in osteoarthritic hypertensive patients].}, author={Pavlicević I and Kuzmanić M and Rumboldt M and Rumboldt Z}, journal={Acta Med Croatica}, volume={65}, number={1}, pages={55-62}}"}}, {"_id": "31525229", "pmid": 31525229, "pmcid": "PMC6746368", "title": "Development of UV spectrophotometry methods for concurrent quantification of amlodipine and celecoxib by manipulation of ratio spectra in pure and pharmaceutical formulation", "journal": "PLoS One", "authors": ["Attimarad M", "Narayanswamy VK", "Aldhubaib BE", "SreeHarsha N", "Nair AB"], "date": "2019-09-16T00:00:00Z", "doi": "10.1371/journal.pone.0222526", "meta_date_publication": "2019", "meta_volume": "14", "meta_issue": "9", "meta_pages": "e0222526", "score": 50050.44, "text_hl": "Recently, the United States Food and Drug Administration approved a new oral dosage preparation of @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine besylate@@@ (@<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@AML@@@) and @CHEMICAL_Celecoxib @CHEMICAL_MESH:D000068579 @@@celecoxib@@@ (@CHEMICAL_Celecoxib @CHEMICAL_MESH:D000068579 @@@CEL@@@) for the management of @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@ and @<m>DISEASE_Osteoarthritis</m> @DISEASE_MESH:D010003 @@@osteoarthritis@@@. ", "citations": {"NLM": "Attimarad M, Narayanswamy VK, Aldhubaib BE, SreeHarsha N, Nair AB. Development of UV spectrophotometry methods for concurrent quantification of amlodipine and celecoxib by manipulation of ratio spectra in pure and pharmaceutical formulation PLoS One. 2019;14(9):e0222526. PMID: 31525229", "BibTeX": "@article{31525229, title={Development of UV spectrophotometry methods for concurrent quantification of amlodipine and celecoxib by manipulation of ratio spectra in pure and pharmaceutical formulation}, author={Attimarad M and Narayanswamy VK and Aldhubaib BE and SreeHarsha N and Nair AB}, journal={PLoS One}, volume={14}, number={9}, pages={e0222526}}"}}]}